logo-loader

Pharmaxis receives $5 million R&D tax incentive as it progresses myelofibrosis treatment

Published: 14:08 14 Oct 2020 AEDT

Pharmaxis Ltd - Pharmaxis receives $5 million R&D tax incentive as it progresses myelofibrosis treatment
Myelofibrosis is a disorder where normal bone marrow tissue is gradually replaced with a fibrous scar-like material

Pharmaxis Ltd (ASX:PXS) (OTCMKTS:PXSLY) (FRA:UUD) has received a research and development tax incentive of $5,048,452 for the 2020 financial year which will be used to fund the ongoing development of innovative medicines with high patient need.

Chief executive officer Gary Phillips said: “The R&D tax incentive is a significant source of non-dilutive funding for the company’s development of new drugs, providing a 43.5% cash payment in relation to eligible research expenditure.”

“Drug development focus”

Phillips said: “Pharmaxis’ current drug development focus is the commencement of a phase 1/2 clinical trial of its pan-LOX inhibitor PXS-505 in myelofibrosis which was recently given permission to proceed by the US Food and Drug Administration (FDA) under its investigational drug program.

“PXS-5505 has also been granted orphan drug designation by the FDA for the treatment of myelofibrosis.”

Syntara to start Phase 2 study targeting MDS

Syntara Ltd (ASX:SNT) CEO Gary Phillips joins Proactive’s Jonathan Jackson to share insights on the company's expansion of its lead drug, SNT-5505, into new medical indications, including a promising Phase 2 study targeting myelodysplastic syndrome (MDS). Phillips highlighted the significance of...

on 14/2/24